Benzinga
Benzinga
Benzinga
jeudi, septembre 24

Sarepta Therapeutics Inc

SRPTNASDAQ
Trade with Public
Trade with Public
$18.39
-0.56-2.96%
À la clôture: Sep 24, 5:00 PM EST
$18.49
0.10.54%
Après les heures: 6:20 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Sarepta Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sarepta Therapeutics (SRPT).

Price Target Range — 6 Quarters

Analyst Consensus — 24 Analysts

9Buy
10Hold
5Sell
Consensus RatingOutperform# Analysts24Avg. Consensus PT$25Upside to Avg. PT+34.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Jul 9, 2026Piper SandlerBiren AminPT CutNeutral$23→$20
Jul 9, 2026Wolfe ResearchAndy ChenUpgradePeer Perform→Outperform$27
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Benzinga Newsdesk

PRO
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price Target

Wolfe Research analyst Andy Chen upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Peer Perform to Outperform and announces $27 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Sell on Sarepta Therapeutics, Maintains $5 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and maintains $5 price target.
Benzinga Newsdesk

PRO
Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.
Benzinga Newsdesk

PRO
Oppenheimer Reiterates Outperform on Sarepta Therapeutics, Maintains $37 Price Target

Oppenheimer analyst Kostas Biliouris reiterates Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and maintains $37 price target.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $31

Mizuho analyst Uy Ear maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $26 to $31.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved